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SUMMARY
The objective is to evaluate the efficacy of galantamine
when a slow titration regimen is employed in Thai
Alzheimer’s disease (AD) patients with or without cerebro-
vascular disease and vascular dementia (VaD).
A 6-month, multicentre, open-label, uncontrolled trial
was undertaken in 75 AD patients. Eligible patients
received an initial galantamine dose of 8 mg/day and
escalated over 5–8 weeks to maintenance doses of 16
or 24 mg/day. Primary efficacy measures were AD
Assessment Scale-cognitive subscale (ADAS-cog) and the
Clinician’s Interview-Based Impression of Change-Plus
version (CIBIC-plus). The Behavioural Pathology in AD
Rating Scale (BEHAVE AD), the AD Cooperative Study
Activities of Daily Living Inventory and Pittsburgh
Sleep Quality Index were the secondary efficacy variables.
Analyses were based on the intent-to-treat population.
Treatment with galantamine showed significant improve-
ment in cognition on the ADAS-cog and CIBIC-plus at
month6.Galantamineshowedfavourableeffectsonactivities
of daily living. Behavioural symptoms and sleep quality were
alsosignificantlyimproved(p < 0.05).Galantaminewaswell
tolerated. The adverse events were mild-to-moderate inten-
sity. The most frequent adverse events commonly reported
werenausea (16.4%), dizziness (9.6%) and vomiting (6.8%).
The results of this study may be consistent with
galantamine being an effective and safe treatment for mild-
to-moderate AD patients with or without cerebrovascular
disease and VaD. Flexible dose escalation of galantamine was
well tolerated. The daily maintenance dose of galantamine was
16 mg/day, followed by a back up dose of 24 mg/day.
Keywords: Alzheimer’s disease; galantamine; acetylcholin-
esterase inhibitors; efficacy; tolerability
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INTRODUCTION
Alzheimer’s disease (AD), a progressive brain disorder, is the
most common cause of dementia among the elderly. It is
characterised by a progressive decline of memory and intellec-
tual abilities, which eventually becomes severe enough to
interfere with functioning in daily living, the overall quality
of life, and ultimately leads to death (1). Cerebrovascular
disease and vascular dementia (VaD) is a chronic condition
which results from reduced blood flow to the brain nerve cells
and can occur together with AD in a condition called ‘mixed
dementia’.
During recent years, both epidemiological and neuropatho-
logical studies have suggested an association between AD and
several vascular-risk factors, such as hypertension, coronary
heart disease, diabetes mellitus, ischaemic white matter lesions
and generalised atherosclerosis (2–4). Further possibilities
include that AD may increase the risk of vascular disease or
that vascular disease may stimulate the AD process (5).
Interestingly, there is considerable overlap between AD and
VaD in terms of both risk factors (vascular-risk factors) and
vascular pathology in the brain (e.g. lacunae and white-matter
lesion) (6,7). There is considerable evidence indicating that, as
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these commonalties, it is reasonable to consider the same treat-
ment strategies for both AD and VaD (9). Therefore, increasing
brain nicotinic functions to a level sufficient to improve synap-
tic plasticity and neuronal survival emerges as a promising
therapeutic approach for treatment of these patients (10).
Galantamine,anoveltreatmentforAD,hasadualmechanism
of action, combining allosteric modulation of nicotinic acetyl-
choline receptors with reversible, competitive inhibition of acet-
ylcholinesterase (11). On the basis of these studies, galantamine
provides a broad spectrum of benefits in cognition, global
function and activities of daily living in AD patients, but no
studies have been conducted in Thai patients before (12–15).
Because differentiation between AD and VaD on clinical
grounds can be difficult, a treatment that provides benefits to
both the groups of patients would be valuable. The study was
designed to determine the therapeutic potential on cognitive
and neuropsychiatric response of galantamine when a slow
titration regimen is employed in Thai Alzheimer’s patients
with or without cerebrovascular disease and VaD. In clinical
practice, slow dose escalation is advocated as a means of
improving the tolerability of cholinergic agents (16). The
current study is to further explore the maximum tolerable
dose of galantamine, using slow dose escalation schedule of
up to 8 weeks in Thai patients.
METHODS
Patients
Men and women with a diagnosis of possible AD who met
the clinical criteria of National Institute of Neurological and
Communicative Disorders and Stroke and AD and Related
Disorders Association (NINCDS/ADRDA) (17) or with pos-
sible VaD according to the National Institute of Neurological
Disorders and Stroke and the Association Internationale pour
la Recherche et l’Enseignement en Neurosciences (NINDS-
AIREN) (18) with the modified Hachinski scale given a score
of 4 or higher were included in the study. They also docu-
mented on a CT or MRI scan less than 12 months before
entry into the study. Eligible patients also showed presence of
mild-to-moderate dementia as evidenced by a Thai Mental
State Examination (TMSE) (19) score of 10–24 and a score
of  12 on the standard cognitive subscale of the AD
Assessment Scale (ADAS-cog) (20). The onset of disease had
to be between ages 40 and 90. In addition, patients had to have
the opportunity to perform certain activities of daily living.
Patients were excluded if they had evidence of other neu-
rodegenerative disorders other than AD, cognitive impair-
ment resulting from acute cerebral trauma, hypoxic cerebral
damage, vitamin deficiency, infection, cerebral neoplasia,
metabolic disease, mental retardation and oligophrenia, or
coexisting medical condition that would limit the patient’s
ability to complete a study. Patients who had received an
investigational medication within the previous 30 days were
also excluded. Any other antidementia medication had to be
discontinued before entry to the study. The use of drugs for
concomitant conditions was permitted during the study, with
the exception of sedative-hypnotics and sedating cough and
cold remedies, which were discontinued 48 h before cognitive
evaluation.
All eligible patients (or a legal representative) and the care-
giver provided written informed consent to participate in the
study, which was conducted according to the Declaration of
Helsinki and its subsequent amendments and approved by
institutional review boards at each participating site.
Study Design
The study was a multicentre, open-label, uncontrolled trial
undertaken in Thailand that ran from January 2002 until
December 2003. Patients received flexible dose of galanta-
mine 16 or 24 mg/day. During dose escalation, patients
received galantamine 4 mg twice daily for weeks 1–4 and
8 mg twice daily for weeks 5–8. At week 8, the investigator
could then increase the dosage to 12 mg twice daily if the
change of patient’s ADAS-cog score is less than 4 points at the
evaluation of week 8 and based on patient tolerance.
Psychometric evaluations, physical and neurological exam-
inations, laboratory determinations and measurements of vital
signs were performed at screening, baseline and (together with
checks for medication compliance and adverse events) at
weeks 8, 12 and 24. Patients also underwent a CT or MRI
scan at screening if this had not been performed within the
previous 6 months.
Assessments
The primary efficacy outcome measures were ADAS-cog to
assess cognitive function and the Clinician’s Interview-Based
Impression of Change–plus caregiver input (CIBIC-plus) to
assess overall clinical response.
Secondary efficacy endpoints included the Behavioural
Pathology in AD Rating Scale (BEHAVE AD), which was
composed of two parts (symptomatology and global rating)
that covers seven domains of behaviours reported in patients
with AD: paranoid and delusional ideation, hallucinations,
activity disturbances, aggressiveness, diurnal rhythm distur-
bances, affective disturbance and anxieties and phobias; the
AD Cooperative Study Activities of Daily Living Inventory
(ADCS/ADL) with scale is a 23-item informant-based assess-
ment scale measuring widely applicable daily activities;
Pittsburgh Sleep Quality Index (PSQI) as a measure of aver-
age sleep quality (21).
Safety and tolerability of study medication were assessed by
rates of discontinuation and treatment-emergent adverse
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values and vital signs, ECG abnormalities and changes on
physical examination.
Statistical Analysis
Data from an earlier validation study of galantamine indi-
cated that 64 patients were needed in the study, to achieve
80% power (a ¼ 0.05) for differences in the assessment
scores between patients treated with galantamine at baseline
and 6 months (22).
All galantamine-treated patients were included in the ana-
lysis of safety, demographic and baseline characteristic data.
Changes in outcome variables, vital signs and bodyweight
from baseline were assessed using two-tailed, paired t-tests.
Analysis of efficacy was based on the intent-to-treat popula-
tion (ITT), which included all patients who took at least one
dose of the study medication and had at least one postbaseline
efficacy assessment. The repeated measure ANOVA model and
paired t-tests were also used in the analysis of change from
baseline score to week 8, 12 and 24 of all categorical efficacy
assessments. All statistical tests were interpreted at the 5%
significance level.
RESULTS
The baseline characteristics are shown in Table 1. In total, 75
patients were enrolled and randomised to treatment and
59(79%) patients completed the study (Figure 1).
Premature withdrawal was due to loss of follow-up, nausea,
vomiting, weight loss, dizziness and rash. At baseline, patients
had a mean TMSE score and ADAS-cog score of 19.7   4.2
and 21.8   1.1, respectively (Table 1). Fifty-two patients
(69%) were classified as mild severity, which is defined by
the TMSE score >18, and the rest 23 (31%) patients were
classified as moderate severity (TMSE   18). The mean daily
dose of galantamine was 21.01   3.9 mg/day. There were 28
(47%) patients maintained on galantamine 16 mg/day and
31 (53%) patients maintained on galantamine 24 mg/day at
end point.
Primary Efficacy Analyses
Improvements in ADAS-cog score over baseline were statisti-
cally significant at weeks 8, 12 and 24 ( 2.10   5.0,
 3.53   5.4 and  3.34   6.8 points, respectively;
p < 0.05) (Figure 1 and Table 2). Significant improvements
in cognitive function from baseline were seen within 3
months after initiating treatment with galantamine
(p < 0.05; Figure 1 and Table 3), especially words recall
task, word recognition task and remembering test instruction
( 0.9   0.1,  1.1   0.5 and  0.5   0.2 points, respect-
ively). Subgroup analysis of patients as classified the disease
severity by TMSE demonstrate that there was a significant
advantage for mild-severity patients compared with moderate-
severity patients (mean change from baseline score at end
point: mild,  2.8   5.7; moderate,  4.6   9.6, Figure 2).
Using the CIBIC-plus as a measure of overall global function
response to galantamine therapy, both groups of patient with
mild and moderate severity could maintain or improve their
CIBIC-plus score at the end of study. At study endpoint, two-
thirds of the patients (67.8%) reported improvement, 25.4%
reported no change and the remaining 6.8% reported
worsened (Table 2).
Secondary Efficacy Analyses
Significant improvements on the BEHAVE-AD were
observed at week 12 evaluations and end point (Table 2;
Figure 3). Results on the ADCS/ADL inventory scores
demonstrated that overall activities of daily living were
improved throughout the study (Table 2; Figure 4).
Significant benefits of galantamine in the quality of sleep
were also observed on the PSQI at week 24 (Table 2;
Figure 5).
Safety Analyses
Generally, adverse events were mild to moderate in intensity
and were transient. The adverse events most commonly
reported were those affecting the gastrointestinal system, the
musculoskeletal system and the nervous system (Table 4). No
clinically meaningful changes from baseline were observed in
vital signs, physical examination findings or ECG status.
There were also no clinically meaningful changes from base-
line in clinical chemistry, haematology or urinalysis tests in
any of the treatment groups.
Table 1 Baseline characteristics
Characteristics
Demography
Male (%) 32 (42.3%)
Female (%) 43 (57.7%)
Age (mean   SE, years) 74.5   0.9
Bodyweight (mean   SE, kg) 53.6   9.9
Cognitive function
ADAS-cog (mean   SE) 21.78   1.1
TMSE (mean   SE) 19.7   4.2
Diagnosis, n (%)
Possible AD 37 (50%)
Possible AD with cerebrovascular disease 32 (42.1%)
Vascular dementia 6 (7.9%)
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; TMSE,
Thai Mental State Examination; AD, Alzheimer’s disease.
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This open-label, uncontrolled study suggests that Thai
patients with mild-to-moderately severe AD with or without
cerebrovascular disease and VaD receiving galantamine
experienced benefits in cognition and global function after
24-week treatment. The clinical relevance of these findings
was emphasised by the improvements seen in both the ADAS-
cog scores and the CIBIC-plus on observed case and ITT
analyses. These broad benefits are desirable in dementia, with
potential favourable effects on the burden of careers and
health-care resources.
Acetylcholinesterase inhibitors have consistently shown
improvements in the cognitive symptoms of AD (23–26),
and available data suggest that galantamine also benefit daily
activities and ameliorate behavioural symptoms (6,26). The
results of ADAS-cog indicated significant beneficial effects of
galantamine on the items associated with attention and execu-
tive function than other items. These observations support the
hypothesis that the allosteric modulation of neuronal nicoti-
nic receptors by galantamine effectively enhances attention
and executive function. Galantamine enhances cholinergic
function by moderating nicotinic acetylcholine receptors
(27,28) and by competitively and reversibly inhibiting acet-
ylcholinesterase (29,30), that is the therapeutic value in
patients with AD (31,32). Subgroup analysis revealed that
patients with both mild and moderate severity had significant
changes on ADAS-cog as compared with baseline (Figure 1).
Thus, moderately severe patients seem to gain the benefit of
treatment more than those with mild severity. This may be
explained by the evidences supporting that severity of AD was
closely correlated to the loss of nicotinic receptors, decrease in
choline acetyltransferase and acetylcholinesterase enzymatic
activity (33–35). Previous studies have demonstrated that
modulation of specific nicotinic receptors in the prefrontal
cortex can lead to increased release of serotonin, glutamate
and dopamine, resulting in improvements in attention, con-
centration and cognition as well as alleviation of aggression
and depression (36,37). Indeed, direct agonists or allosteric
modulators of presynaptic nicotinic acetylcholine receptors
may activate not only the cholinergic system but also other
noncholinergic pathway that are impaired in AD. This raises
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Figure 1 Mean subset scores of Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) over 6 months (intent-to-treat
population analysis). *p < 0.01 vs. baseline
Table 2 Efficacy outcomes in the total population after 6 months
Assessment Mean change from baseline
Primary efficacy outcomes
ADAS-cog (mean   SE)  3.34   0.9
CIBIC-plus [number (%) patients]
Improved 11 (18.6%)
No change 2 (3.4%)
Worsened 9 (15.3%)
Secondary efficacy outcomes
BEHAVE-AD†  2.8   7.5*
ADCS/ADL‡ 2.4   17.9*
PSQI† 1.2   2.4
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CIBIC-
plus, Clinician’s Interview-Based Impression of Change–plus caregiver input;
BEHAVE-AD, Behavioural Pathology in AD Rating Scale; ADCS/ADL,
Activities of Daily Living Inventory; PSQI, Pittsburgh Sleep Quality Index.
*p < 0.05;†Negativechangesindicateimprovement;‡Positivechangesindicate
improvement.
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Mean   SD
ADAS-cog domain Baseline Week 8 Week 12 Week 24
Word-recall task 6.4   0.2 6.0   0.2* 5.4   0.3* 5.5   0.2*
Naming 0.3   0.1 0.2   0.1 0.2   0.1 0.2   0.1
Commands 1.4   0.1 1.4   0.2 1.1   0.1 1.2   0.1
Constructional 1.2   0.1 1.1   0.1 1.1   0.1 1.2   0.1
Ideational 0.8   0.1 0.9   0.1 0.8   0.1 0.7   0.1
Orientation 3.1   0.3 3.2   0.3 3.2   0.8 3.2   0.3
Word recognition task 5.4   0.5 4.6   0.4 4.3   0.5* 4.3   0.5*
Remembering 1.7   0.2 1.4   0.2* 1.2   0.2* 1.3   0.2*
Spoken language ability 0.4   0.1 0.2   0.1 0.2   0.1 0.2   0.1
Comprehension 0.6   0.1 0.3   0.1* 0.4   0.1* 0.4   0.1*
Word-finding difficulty 0.5   0.1 0.4   0.1 0.3   0.1 0.2   0.1
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; *p < 0.05 vs. baseline.
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Figure 2 Mean change from baseline in cognitive abilities (as assessed with Alzheimer’s Disease Assessment Scale-cognitive subscale) over 6
months (intent-to-treat population analysis); results in the total population and in patients with moderate and mild groups. **p < 0.01,
*p < 0.05 vs. baseline
EFFICACY STUDY OF GALANTAMINE IN POSSIBLE AD 537
ª 2006 The Authors
Journal compilation ª 2006 Blackwell Publishing Ltd Int J Clin Pract, May 2006, 60, 5, 533–540the possibility that, compared with currently available treat-
ment for AD, galantamine may produce additional clinical
benefits (22).
Concerning global assessment, CIBIC-plus was used in this
study. We found that the majority of patients were assessed to
have improved at the end of study period. No difference on
treatment effect between patients with mild and moderate
severity was observed in this study. The patients had better
outcome on the ADCS/ADL relative to baseline; even the
difference in mean change between baseline and end point
was not statistically significant. A larger sample size might
have detected clearer differences in efficacy of this outcome.
Over the 6-month study period, galantamine also signifi-
cantly improved behaviour and quality of sleep from baseline.
The adverse events associated with galantamine in this
study were generally those expected from cholinergic stimula-
tion. The adverse event was mild-to-moderate severity,
occurred primarily during the dose escalation phase and
may be reduced further using a slower dose escalation (38).
The main objectives of the study were to investigate whether
the tolerability of galantamine was improved with slow dose
escalation. The slow introduction of galantamine was well
tolerated. Patients in the low-dose galantamine (16 mg/day)
group experienced fewer adverse events than those receiving
the 24 mg/day dose of galantamine. This finding suggests
that the maintenance dose of galantamine should be 16 mg/
day while 24 mg/day was used as a back-up dose for those
patients who did not respond to 16 mg/day.
Long-term, placebo-controlled studies are the ideal way to
assess the duration of benefit of treatments in AD. However,
such studies are difficult to conduct because of the ethical
reasons and high drop out rates. An alternative method is to
conduct an open-label study (25,39). In conclusion, the
results of this long-term, open-label study suggest that galan-
tamine may be effective in the treatment of dementia due to
AD and in dementia due to cerebrovascular disease with
tolerable adverse effects. These evidences may provide a treat-
ment option to a broader range of patients and therapeutic
effects that will give important benefits to patients with
dementia.
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in AD Rating Scale over 6 months (intent-to-treat population ana-
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Table 4 Number (%) of patients with adverse events during treatment with galantamine
Number of Severity
Adverse event Total number (%) Mild Moderate Severe
Nausea 12 (16.4) 6 3 3
Vomiting 5 (6.8) 2 1 2
Abdominal pain 3 (4.1) 2 1 –
Diarrhoea 2 (2.7) 2 – –
Muscle cramp 2 (2.7) 2 – –
Fatigue 2 (2.7) 2 – –
Headache 2 (2.7) 2 – –
Dizziness 7 (9.6) 6 1 –
Weight loss 11 (15.1) 9 2 –
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